Screener
Jade Biosciences JBIO Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Jade Biosciences in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Jade Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:27 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212088
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Accrued expenses and other current liabilities | 14,852 | 9,419 |
| Related party accrued expenses and other current liabilities | 794 | 4,969 |
| Warrant liability, related party | 2,667 | — |
| Total current liabilities | 22,292 | 16,539 |
| Long-term liabilities: | ||
| Long-term lease liability | 679 | 724 |
| Total liabilities | 22,971 | 17,263 |
| Commitments and contingencies (Note 12) |
Item 1. Financial Statements.
FAQ
- What is Jade Biosciences's total current liabilities?
- Jade Biosciences (JBIO) reported total current liabilities of $22.29M in Q1 2026.
- How has Jade Biosciences's total current liabilities changed year-over-year?
- Jade Biosciences's total current liabilities increased by 822.3% year-over-year, from $2.42M to $22.29M.
- What is the long-term trend for Jade Biosciences's total current liabilities?
- Over 5 years (2020 to 2025), Jade Biosciences's total current liabilities has grown at a 56.3% compound annual growth rate (CAGR), from $1.77M to $16.54M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Jade Biosciences's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude